Adial Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing therapies for addiction and related disorders, recently reached a significant milestone by successfully dosing the first patient in a pharmacokinetics (PK) study for AD04, a potential treatment for Alcohol Use Disorder (AUD). This study aims to optimize the design elements necessary for upcoming pivotal Phase 3 trials in the United States, while also supporting ongoing partnership discussions. In addition, Adial Pharmaceuticals received the final reimbursement payment from Adovate, LLC, marking an important financial achievement for the company.
Key Facts from the s:
Pharmacokinetics Study of AD04 for AUD Treatment
- Adial Pharmaceuticals has initiated a pharmacokinetics study for AD04, a therapeutic candidate targeting Alcohol Use Disorder.
- The primary goal of the study is to optimize the design elements required for its subsequent Phase 3 clinical trials in the United States.
- The study also plays a crucial role in facilitating ongoing partnership discussions related to the development of AD04 and potential distribution networks.
Final Reimbursement Payment from Adovate
- Adial Pharmaceuticals received the final development cost reimbursement payment of $350,000 from Adovate, LLC.
- This payment was made under the terms of the final asset purchase agreement executed with Adovate for the acquisition of the assets and business of the Company’s wholly-owned subsidiary, Purnovate, Inc.
- The agreement encompasses potential milestones payments totaling up to $11 million in development and approval milestones, along with $50 million in additional commercial milestones, making the total consideration up to $83 million.
- Furthermore, Adial Pharmaceuticals acquired a 15% equity stake in Adovate and is en
Comments